When it comes to har­ness­ing da­ta for health­care and the life sci­ences, a rich in­fra­struc­ture of ex­pan­sive da­ta col­lect­ed and mea­sured with the right tools are es­sen­tial to un­cov­er new in­sights and ad­vance new prod­ucts. And to build that, you need ac­cess to di­verse tal­ents backed by a pa­tient in­vestor.

Jim Tanan­baum

Just ask Vik Ba­jaj. The for­mer UC Berke­ley re­searcher first left acad­e­mia for Ver­i­ly, Google’s for­ay in­to life sci­ences, where he saw the meth­ods of mar­ry­ing com­pu­ta­tion and bi­ol­o­gy were near­ing ma­tu­ri­ty. Af­ter a few years as CSO there he moved on to Grail work­ing to­wards the ear­ly de­tec­tion of can­cer — an­oth­er da­ta in­ten­sive en­deav­or — be­fore land­ing his cur­rent role as man­ag­ing di­rec­tor of Fore­site Cap­i­tal.

Yet in spite of all the progress he’s seen and helped prop­a­gate, it’s not quite there yet. There is still a gap be­tween what’s cur­rent­ly avail­able and what he sees as a trans­for­ma­tion in health­care en­abled by the in­for­ma­tion rev­o­lu­tion.

“Re­al­ly what we per­ceive — and ob­vi­ous­ly I’m not alone in stat­ing this — is that there is an eco­nom­ic cri­sis in our health­care sys­tem where we are spend­ing so much of our na­tion­al prod­uct on health­care and yet we have out­comes that are ac­tu­al­ly in de­cline in many pop­u­la­tions,” Ba­jaj told End­points News. “And we think that there are many ways to make that in­dus­try more ef­fi­cient and more re­spon­sive to the needs of its pa­tients, but ob­vi­ous­ly this idea of us­ing da­ta sci­ence, the pow­er of mea­sure­ments, of un­der­stand­ing of ex­per­i­ments is fun­da­men­tal to gen­er­at­ing re­li­able ev­i­dence that will solve some of these large health­care prob­lems.”

The no­tion is what spurred him and Fore­site CEO Jim Tanan­baum to launch Fore­site Labs, an en­tre­pre­neur­ial in­cu­ba­tor de­signed to nur­ture some of the foun­da­tion­al com­pa­nies at the nexus of da­ta sci­ence and health­care.

Fore­site Labs re­moves three of the biggest bar­ri­ers for star­tups in this space, ac­cord­ing to Ba­jaj: It of­fers a pool of pub­lic and pro­pri­etary datasets, which would be ex­pen­sive for any one com­pa­ny to gen­er­ate; an analy­sis plat­form con­sist­ing of the lead­ing tools to aid with clin­i­cal ap­pli­ca­tion of da­ta; as well as a sea­soned team of 20-plus — be­tween the Boston and San Fran­cis­co of­fices — to of­fer sci­en­tif­ic, tech­ni­cal and busi­ness sup­port. As part of that, they al­so hook com­pa­nies up with part­ners for re­sources such as lab space.

Cor­re­spond­ing­ly, he sees three types of ven­tures that would ben­e­fit the most from their in­cu­ba­tion — and that they would be most in­ter­est­ed in.

The first in­volves ther­a­peu­tic op­por­tu­ni­ties cen­tered around func­tion­al ge­nomics; the sec­ond group build the in­fra­struc­ture need­ed for clin­i­cal de­vel­op­ment us­ing re­al-world ev­i­dence; the third cat­e­go­ry would look in­to per­son­al­ized health­care de­liv­ery based on in­di­vid­ual as­sess­ment of dis­ease risk.

Out­side of these high lev­el de­tails, though, he’s let­ting lit­tle else slip about what Fore­site Labs has been work­ing on over the past year. The cap­i­tal Fore­site has to de­ploy, the num­ber of ven­tures they would back at any one time, the ca­pa­bil­i­ties they are con­sid­er­ing adding — these are all stay­ing un­der wraps.

One thing we know, though, is that Fore­site has plen­ty of fire­pow­er and pa­tience to seed com­pa­nies where they see po­ten­tial. Last May the firm closed its fourth fund at a record $668 mil­lion and vowed to beef up their ma­chine learn­ing chops to en­able bet­ter in­vest­ment de­ci­sions.

“We’re get­ting in­to this area where we be­lieve through long ex­pe­ri­ence has tremen­dous po­ten­tial,” he said. “But it’s a po­ten­tial that will be re­al­ized rough­ly over the next decade. […] That means that we’re go­ing to be ini­tial­ly very mea­sured in what we do, and very de­lib­er­ate in launch­ing a few high qual­i­ty com­pa­nies with­out putting num­bers or tar­gets on it.”

The team of ex­perts they’ve re­cruit­ed to Fore­site Labs, he added, should prove to be the great­est as­set over the long run. They in­clude:

• Alex Block­er, head of da­ta sci­ence (for­mer­ly of Grail and Ver­i­ly)
• Rick Dewey, head of ge­nomics dis­cov­ery (for­mer­ly of the Re­gen­eron Ge­net­ics Cen­ter)
• Damien Soghoian, head of op­er­a­tions and strat­e­gy (for­mer­ly of Ver­i­ly)
• Paul Da Sil­va Jar­dine, head of drug dis­cov­ery (for­mer­ly of Pfiz­er)

On top of that, he’s as­sem­bled a star-stud­ded sci­en­tif­ic ad­vi­so­ry board fea­tur­ing Math­ai Mam­men of J&J, Pao­la Ar­lot­ta of Har­vard, Eu­an Ash­ley of Stan­ford, Calum MacRae of Brigham and Women’s Hos­pi­tal, Steve Finkbein­er of Glad­stone, Jeff Hu­ber and Alex Ar­a­va­nis of Grail, as well as Rus­lan Medzhi­tov of the Howard Hugh­es Med­ical In­sti­tute.

“Ob­vi­ous­ly it will be an area that will be much big­ger than what Fore­site Labs does, but I think that we are a lit­tle bit ahead and so poised to have a huge in­flu­ence over the trans­for­ma­tion,” Ba­jaj said.

By Natasha Cowan, Content Marketing Manager at Blue Latitude Health.
Many stakeholders are confused by novel precision medicines, including patients and healthcare professionals. So, how can industry help them to navigate this complexity?

Precision medicine represents a new paradigm in healthcare. It embodies the shift from treating many patients with the same therapy, to having the tools to identify the best treatment for every patient.

→ After Teva spinout 89bio recently announced that its IPO was being held up, the company is back in the game offering 5,304,687 shares at a price of $16 per share. The company has raised $84.9 million IPO in gross proceeds and will be listed under the ticker symbol $ETNB. BofA Securities, SVB Leerink and RBC Capital Markets are the joint book-running managers for the offering. Oppenheimer & Co is the co-manager for the offering.
→ Looking to amp up its presence in Japan’s hospitals, Novartis has struck a deal to buy out Aspen’s portfolio of generics in the world’s third largest healthcare market. The pharma giant is paying $440 million for Aspen’s Japanese subsidiary.
→ Novartis said tropifexor, a non-bile acid FXR agonist, has scored on several key biomarkers of NASH in a Phase IIb trial, including reductions in hepatic fat, alanine aminotransferase and body weight compared to a placebo at 12 weeks.

Its frontline and single-agent aspirations have been set back, but Bristol-Myers Squibb just took a big step forward in its efforts to apply its checkpoint inhibitor Opdivo to liver cancer. The FDA has granted breakthrough status and priority review to a combination, second-line treatment.

The designation is for Opdivo (nivolumab) in combination with Yervoy (ipilimumab),  for treating advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. The PD-L1 drug was already approved as a single-agent, second-line treatment for HCC. A PDUFA date was set for March 10, 2020 — just 4 months from now.

Lipocine’s latest attempt at securing approval for its oral testosterone drug has fizzled yet again.

The Utah-based drug developer on Monday said the FDA has spurned its marketing application, indicating that some efficacy data on the drug, Tlando, was not up to scratch to treat male hypogonadism, a condition characterized by low production of the hormone testosterone, which is responsible for maintaining muscle bulk, bone growth, and sexual function.

When RegenxBio disclosed that the FDA had placed a partial clinical hold on one of its lead gene therapies, execs outlined several customary next steps: continuing assessment and monitoring, delaying a related IND filing, and working with the FDA to address the matter.

As it turned out, they were planning something much less mundane. Two days after announcing the hold in its Q3 update, RegenxBio filed a lawsuit seeking to set it aside, the FDA Law Blog noted.

Roche is working on putting together a late-stage study for its monoclonal antibody Gazyva in patients with severe kidney disease associated with lupus after a combination approach helped patients in a mid-stage study.

The 125-patient NOBILITY trial evaluated Gazyva, combined with standard-of-care treatment mycophenolate mofetil or mycophenolic acid and corticosteroids, versus standard treatment alone. The combo met the main goal of inducing a statistically superior complete renal response (CRR) of 40% at week 76, versus 18% in patients given standard treatment, Roche said.